研究者業績

松田 勇紀

マツダ ユウキ  (Yuki Matsuda)

基本情報

所属
藤田医科大学 臨床研究・開発教育学 講師
(兼任)医学教育企画室 室員
東京慈恵会医科大学 精神医学講座 非常勤講師
国立研究開発法人国立精神・神経医療研究センター 精神診療部 研究生
学位
学士(医学)(2010年3月 藤田医科大学)
博士(医学)(2016年3月 藤田医科大学大学院)
社会健康医学修士(専門職)(2024年3月 京都大学大学院)

researchmap会員ID
B000247656

外部リンク

受賞

 5

論文

 76
  • Yuki Matsuda, Shinsuke Kito, Fumiyo Hiraki, Takuji Izuno, Katsuomi Yoshida, Motoaki Nakamura, Fumitoshi Kodaka, Ryuichi Yamazaki, Nanase Taruishi, Shinichi Imazu, Tetsufumi Kanazawa, Takahiro Mekata, Sotaro Moriyama, Masataka Wada, Shinichiro Nakajima, Kazuyuki Sawada, Shinya Watanabe, Shun Takahashi, Yuuki Toi, Daisuke Hayashi, Shun Igarashi, Ko Fujiyama, Shunichiro Ikeda, Hiroshi Tateishi, Ryohei Kojima, Kengo Sato, Shuken Boku, Minoru Takebayashi, Moritaka Ogura, Atsuhiko Takaya, Kenji Endo, Akira Kita, Hisatoshi Arai, Hisashi Kamimura, Koji Matsuo, Kenzo Denda, Sachi Yamashiro, Daisuke Yoshioka, Junichiro Kizaki, Masaru Mimura, Yoshihiro Noda
    Psychiatry research 342 116263-116263 2024年11月10日  査読有り筆頭著者
    The objective of this study was to reveal the effectiveness of repetitive transcranial magnetic stimulation (rTMS) for Japanese patients with treatment-resistant depression (TRD) in clinical practice, based on real-world data from a nationwide multicenter observational study in Japan. Clinical data of patients with TRD treated with rTMS (NeuroStar TMS treatment system) under public insurance coverage were retrospectively collected from 21 institutes nationwide between June 2019 and December 2023. Depression severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17). Response and remission were defined as ≥50 % reduction from baseline and ≤7 points on the HAMD-17, respectively. The primary outcome was the changes in the HAMD-17 score from baseline to the endpoint following rTMS. Data from 497 patients with TRD were candidates for this study. The HAMD-17 scores (mean (SD)) improved significantly from 18.9 (5.3) to 9.7 (6.6), respectively. The response and remission rates at the end of rTMS therapy as assessed by the HAMD-17 were 53.5 % and 42.8 %, respectively. The dropout rate due to adverse effects was 4.2 %, and the treatment was generally well tolerated. No convulsive seizures or manic changes were observed. These results indicate that conventional rTMS is effective and safe in Japanese patients with TRD.
  • Ami Nakazawa, Yuki Matsuda, Ryuichi Yamazaki, Nanase Taruishi, Shinsuke Kito
    Neuropsychopharmacology reports 2024年11月9日  査読有り
    AIM: This study aimed to elucidate the effects of repetitive transcranial magnetic stimulation (rTMS) on weight, body mass index (BMI), and lipid metabolism in patients with treatment-resistant depression (TRD). METHODS: This retrospective observational study included patients with TRD who received rTMS treatment at the Jikei University Hospital from September 2018 to August 2021. The patients were diagnosed based on the DSM-5 and ICD-10 criteria and treated using the NeuroStar TMS System. For 3-6 weeks, 10-Hz rTMS was administered to the left dorsolateral prefrontal cortex at 120% motor threshold. The primary outcomes were changes in weight and BMI, whereas the secondary outcomes included changes in total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels, thyroid function indicators, as well as HAMD-17, HAMD-24, and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Statistical analysis was conducted using paired t-tests and repeated measures ANOVA. RESULTS: Among the 34 patients (20 men and 14 women) included, no significant changes were observed in weight or BMI after rTMS treatment (average weight reduction: -0.50 kg, 95% CI: -0.14 to 0.56, p = 0.24; average BMI reduction: -0.21, 95% CI: -0.10 to 0.61, p = 0.15). However, significant reductions in total, HDL, and LDL cholesterol levels and FT4 were observed. Furthermore, the HAMD-17, HAMD-24, and MADRS scores significantly increased post-treatment. CONCLUSION: rTMS treatment did not affect weight or BMI in patients with TRD but is believed to improve lipid metabolism.
  • Daisuke Hayashi, Ryuichi Yamazaki, Yuki Matsuda, Shun Igarashi, Nanase Taruishi, Fumitoshi Kodaka, Masahiro Shigeta, Shinsuke Kito
    Neuropsychobiology 1-8 2024年6月18日  査読有り
    INTRODUCTION: The clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression (TRD) in Japan has not been adequately investigated. Furthermore, the relationship between stimulation-site pain and the antidepressant effects of rTMS has not been thoroughly examined. Therefore, this study aimed to clarify (1) the real-world efficacy and safety of rTMS for TRD in Japan and (2) the relationship between stimulation-site pain and clinical improvement of depressive symptoms. METHODS: We conducted a retrospective observational study involving 50 right-handed patients with TRD. All patients received high-frequency rTMS for up to 6 weeks. Depressive symptoms were assessed using the Montgomery-Åsberg depression rating scale (MADRS). Pain at the stimulation site was reported by the patients using a visual analog scale (VAS) after each session. Remission and response rates at 3 and 6 weeks were calculated based on the MADRS scores. The correlation between changes in the MADRS and VAS scores was examined. RESULTS: Remission and response rates were 36% and 46%, respectively, at the end of 3 weeks, and 60% and 70%, respectively, at 6 weeks. At the end of the treatment, there was significant correlation between the reduction of MADRS and VAS scores (r = 0.42, p = 0.003). CONCLUSION: This study demonstrates the clinical efficacy of rTMS in Japan and the correlation between its antidepressant effects and stimulation-site pain.
  • Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Jonas Wilkening, Roberto Goya-Maldonado, Martin Tik, Nolan R Williams, Shinsuke Kito, Nakao Iwata
    Molecular psychiatry 2024年6月6日  査読有り
    In clinical practice, theta burst stimulation (TBS) presents as a more efficient and potentially more effective therapeutic modality than conventional repetitive transcranial magnetic stimulation (rTMS), as it allows for the delivery of more stimuli in less time and at similar intensities. To date, accelerated treatment plans according to various continuous (cTBS) and intermittent TBS (iTBS) protocols for depression have been proposed. To investigate which of the TBS protocols provided a favorable risk-benefit balance for individuals with depression, this systematic review and random-effects model network meta-analysis was conducted. The study outcomes included response rate (primary), depression symptom improvement, remission rate, all-cause discontinuation rate, incidence of switch to mania, and incidence of headache/discomfort at treatment site. In this meta-analysis, a total of 23 randomized controlled trials (n = 960, mean age = 41.88 years, with 60.78% females) were included. Approximately 69.57% of the trials included individuals with an exclusive diagnosis of major depressive disorder. The following six TBS protocols (target) were evaluated: cTBS (right-dorsolateral prefrontal cortex [R-DLPFC]), cTBS (R-DLPFC) + iTBS (left-DLPFC [L-DLPFC]), iTBS (L-DLPFC), iTBS (L-DLPFC) + iTBS (R-DLPFC), iTBS (left-dorsomedial prefrontal cortex) + iTBS (right-dorsomedial prefrontal cortex), and iTBS (occipital lobe). Compared to sham, cTBS (R-DLPFC) + iTBS (L-DLPFC), iTBS (L-DLPFC), and iTBS (occipital lobe) had a higher response rate (k = 23); cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) dominated in the depression symptom improvement (k = 23); and iTBS (L-DLPFC) had a higher remission rate (k = 15). No significant differences were found for all-cause discontinuation rate (k = 17), incidence of switch to mania (k = 7), and incidence of headache/discomfort at treatment site (k = 10) between any TBS protocols and sham. Thus, cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) demonstrate favorable risk-benefit balance for the treatment of depression.
  • Shun Igarashi, Kyoji Okita, Daisuke Hayashi, Ryuichi Yamazaki, Yuki Matsuda, Takamasa Noda, Koichiro Watanabe, Shinsuke Kito
    Psychiatric research and clinical practice 6(2) 63-64 2024年  査読有り
  • Daisuke Hayashi, Shun Igarashi, Ryuichi Yamazaki, Yuki Matsuda, Takuma Inagawa, Yutaka Kawakami, Kyoji Okita, Takamasa Noda, Tomiki Sumiyoshi, Shinsuke Kito
    Asian Journal of Psychiatry 90 103806-103806 2023年12月  査読有り
  • Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Masaki Kato, Nakao Iwata
    Psychiatry and clinical neurosciences 2023年11月20日  査読有り
  • Taro Kishi, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Hikaru Hori, Masaki Kato, Nakao Iwata
    Neuropsychopharmacology reports 2023年8月30日  査読有り
    INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p < 0.00001], response to treatment [RR (95% CI) = 1.23 (1.13, 1.32), p < 0.00001], and remission rate [RR (95% CI) = 1.30 (1.16, 1.45), p < 0.00001]. Although all-cause discontinuation was not significantly different between the treatment groups, the pooled antidepressant group showed a higher discontinuation rate due to adverse event [RR (95% CI) = 1.60 (1.13, 2.26), p = 0.007] and a higher incidence of at least one adverse event than the placebo group [RR (95% CI) = 1.13 (1.08, 1.18), p < 0.00001]. DISCUSSION: We concluded that newer antidepressants are effective for Japanese adults with MDD although the clinicians must monitor the health conditions of these individuals.
  • Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
    Psychiatry research 328 115452-115452 2023年8月28日  査読有り
    Our meta-analysis demonstrated that intermittent theta burst stimulation (iTBS)/bilateral-TBS (Bi-TBS) and high-frequency repetitive transcranial magnetic stimulation (HF-rTMS)/bilateral-rTMS (Bi-rTMS) had similar efficacy, acceptability, and safety profiles for antidepressant treatment-resistant major depressive disorder (AD-TRD). In our sensitivity analysis that excluded a study that compared Bi-TBS with Bi-rTMS for older adults, all efficacy outcomes were also comparable between iTBS and HF-rTMS. Because iTBS does not require higher stimulation intensity and a longer stimulus time than conventional HF-rTMS protocols, we speculated that for those with AD-TRD, iTBS/Bi-TBS is a more helpful therapeutic modality in clinical practice than HF-rTMS/Bi-rTMS.
  • Ryuichi Yamazaki, Yuki Matsuda, Mari Oba, Hideki Oi, Shinsuke Kito
    BMC psychiatry 23(1) 437-437 2023年6月16日  査読有り
    BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is a widely used treatment for major depressive disorder (MDD), and its effectiveness in preventing relapse/recurrence of MDD has been explored. Although few small sample controlled studies exist, the protocols of maintenance rTMS therapy were heterogeneous and evidence of its effectiveness is not sufficient. Thus, this study aims to evaluate whether maintenance rTMS is effective in maintaining the treatment response in patients with MDD with a large sample size and feasible study design. METHODS: In this multicenter open-labelled parallel-group trial we plan to recruit 300 patients with MDD who have responded or remitted to acute rTMS therapy. Participants would be classified into two groups according to their preference; the maintenance rTMS and pharmacotherapy group, and the pharmacotherapy only group. The protocol of maintenance rTMS therapy is once a week for the first six months and once biweekly for the second six months. The primary outcome is the relapse/recurrence rates during 12 months following enrollment. Other measures of depressive symptoms and recurrence/relapse rates at different time points are the secondary outcomes. The primary analysis is the between-group comparison adjusted for background factors using a logistic regression model. We will perform the group comparison with inverse probability of treatment weighting as the sensitivity analysis to ensure the comparability of the two groups. DISCUSSION: We hypothesize that maintenance rTMS therapy could be an effective and safe treatment for preventing depressive relapse/recurrence. Considering the limitation of potential bias owing to the study design, we plan to use statistical approaches and external data to avoid overestimation of the efficacy. TRIAL REGISTRATION: Japan Registry of Clinical Trials, ID: jRCT1032220048 . Registered 1 May 2022.
  • Ryuichi Yamazaki, Hiroyuki Ohbe, Yuki Matsuda, Shinsuke Kito, Masahiro Shigeta, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
    Asian journal of psychiatry 84 103581-103581 2023年4月6日  査読有り
    BACKGROUND: This study aimed to evaluate the effects of medical fee revisions aimed to reduce psychotropic polypharmacy in Japan on the proportion of psychotropic polypharmacy in discharge prescriptions for patients with major depressive disorder (MDD) or bipolar disorder (BD) using a nationwide inpatient database. METHODS: In this retrospective cohort study, we used the Diagnosis Procedure Combination database to identify patients with MDD or BD discharged between April 2012 and March 2021. We targeted medical fee revisions in October 2014, April 2016, and April 2018. The major outcome was the monthly proportion of psychotropic polypharmacy in prescription at discharge using the criteria following the April 2018 revision (antidepressants ≥3, antipsychotics ≥3, anxiolytics ≥3, hypnotics ≥3, or sum of anxiolytics and hypnotics ≥4). We performed interrupted time series analyses to evaluate the changes in level and trend between pre- and post-revisions. RESULTS: We identified 63,289 and 33,780 patients with MDD and BD respectively in the entire study period. In both the patient groups, there were significant decreases in the proportion of psychotropic polypharmacy at revision in October 2014, and no significant trend and level change at revision were observed in April 2016 and April 2018, with a few exceptions. CONCLUSIONS: The medical fee revisions aimed to reduce psychotropic polypharmacy in Japan might have had a limited impact on discharge prescriptions for patients with MDD and BD.
  • Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
    Molecular psychiatry 2023年4月5日  査読有り
  • Taro Kishi, Kenji Sakuma, Yuki Matsuda, Shinsuke Kito, Nakao Iwata
    Bipolar disorders 2023年1月20日  査読有り
  • Yuki Matsuda, Kenji Sakuma, Taro Kishi, Kosei Esaki, Shinsuke Kito, Masahiro Shigeta, Nakao Iwata
    Brain stimulation 16(2) 458-461 2023年  査読有り筆頭著者
  • Taro Kishi, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, Yuki Matsuda, Masaki Kato, Nakao Iwata
    Molecular psychiatry 28(3) 974-976 2022年12月23日  査読有り
  • Yuka Shirakawa, Ryuichi Yamazaki, Yosuke Kita, Yuzuki Kitamura, Yasuko Okumura, Yuki Inoue, Yuki Matsuda, Fumitoshi Kodaka, Masahiro Shigeta, Shinsuke Kito
    Neuroreport 33(11) 470-475 2022年8月3日  査読有り
    Patients with major depressive disorder (MDD) exhibit several clinical symptoms including difficulties in flexible thinking. Flexible thinking mainly relies on a cognitive ability called shifting; however, the mechanisms underlying shifting in patients with MDD have not yet been clarified. Therefore, we conducted a preliminary intervention study to clarify the association between depression and shifting ability. We examined the hemodynamic responses in the frontal regions during the shifting task using functional near-infrared spectroscopy (fNIRS) in 21 patients with MDD who were treated using high-frequency repetitive transcranial magnetic stimulation (rTMS). Behavioral performance on the shifting task did not change between pre- and posttreatments, whereas patients who responded well to rTMS treatment showed a significant decrease in hemodynamic responses posttreatment. On the other hand, the poor responders did not show significant changes in the hemodynamic responses between pre- and posttreatments. These results suggest that the good responders were successfully remedied with rTMS treatment and did not need effortful activity in frontal regions for shifting, which made their brain activity more efficient.
  • Ryuichi Yamazaki, Hiroyuki Ohbe, Yuki Matsuda, Shinsuke Kito, Masahiro Shigeta, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
    Journal of affective disorders 312 245-251 2022年6月24日  査読有り
    OBJECTIVES: Electroconvulsive therapy (ECT) is a widely used treatment for bipolar depression; however, evidence of its effectiveness is not sufficient. This study therefore aimed to evaluate whether early ECT is associated with reduced length of hospital stay. METHODS: In this retrospective cohort study using the Japanese Diagnosis Procedure Combination database, we identified patients admitted for bipolar depression between April 2010 and March 2018. The primary outcome was length of hospital stay, and the secondary outcome was clinical outcomes and total hospitalization costs. Propensity score-matched analyses were performed to compare the outcomes between patients who received ECT within 8 days of admission (early ECT group) and those who did not (control group). RESULTS: We identified 5941 eligible patients, comprising 219 in the early ECT group and 5722 in the control group. After 1:4 propensity score matching, patients in the early ECT group had significantly shorter lengths of hospital stay than those in the control group (53 days in the early ECT group and 73 days in the control group; difference: -20.2 days; 95 % confidence interval: -29.2 to -11.2 days). There was no significant difference in total hospitalization costs between the two groups. In-hospital mortality and fatal complications were rare in both groups. The result was similar in the sensitivity analysis using inverse probability of treatment weighting. LIMITATIONS: Our study was limited by retrospective design and the possibility of unmeasured confounders. CONCLUSIONS: Early ECT was associated with reduced length of hospital stay without increasing total hospitalization costs in patients with bipolar depression.
  • Yuki Matsuda, Rema Terada, Kodai Yamada, Ryuichi Yamazaki, Akihiko Nunomura, Masahiro Shigeta, Shinsuke Kito
    Psychiatry and Clinical Neurosciences Reports 1(2) e11 2022年6月  査読有り筆頭著者責任著者
  • Ryuichi Yamazaki, Yuki Inoue, Yuki Matsuda, Fumitoshi Kodaka, Yuzuki Kitamura, Yosuke Kita, Masahiro Shigeta, Shinsuke Kito
    Psychiatry research 310 114444-114444 2022年2月13日  査読有り
    The factors associated with the clinical outcomes of repetitive transcranial magnetic stimulation (rTMS) in patients with major depressive disorder (MDD) remain largely unexplored. Therefore, this study aimed to examine whether rTMS can change the functional laterality of the prefrontal hemodynamic response and whether baseline functional laterality can predict the clinical outcomes of rTMS using functional near-infrared spectroscopy (fNIRS). We included 19 patients with MDD who were treated with high-frequency rTMS. The verbal fluency task was used as the activation task. We calculated the laterality index (LI) based on the task-related oxygenation response in the frontal region. First, the LI was compared before and after rTMS treatment. Second, the reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) score was compared between the rightward dominance group (pre-LI < 0) and the leftward dominance group (pre-LI ≥ 0). The findings showed a significant change in the LI after rTMS treatment. The rightward dominance group had a significantly greater reduction in MADRS score than the leftward dominance group. Subsequently, the laterality of the task-related hemodynamic response of the prefrontal region shifted leftward following left high-frequency rTMS treatment. Thus, the pre-LI calculated using fNIRS data is a possible predictor of rTMS outcomes in patients with MDD.
  • Yuki Matsuda, Ryuichi Yamazaki, Masahiro Shigeta, Shinsuke Kito
    Asian journal of psychiatry 68 102970-102970 2021年12月17日  査読有り筆頭著者責任著者
  • Yuki Matsuda, Ryuichi Yamazaki, Masahiro Shigeta, Shinsuke Kito
    Neuropsychopharmacology reports 2021年10月22日  査読有り筆頭著者責任著者
    AIM: Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique that shows potential for treating psychiatric disorders. Although several studies have sought to investigate new TMS modalities for the treatment of various psychiatric disorders, no study has yet examined publication trends in research on TMS modalities for psychiatric disorders. This study investigated publication trends in TMS research for 13 psychiatric disorders, including addiction, dementia, major depressive disorder (MDD), and obsessive-compulsive disorder (OCD), and schizophrenia, as well as 9 TMS modalities, including bilateral stimulation, deep TMS, high-frequency stimulation, low-frequency stimulation, and theta burst stimulation. METHODS: Articles published in PubMed from 1985 to 2019 were searched to determine the number of published articles for each year in each category using the "Results by year" tool from the PubMed database. RESULTS: Over the past 30 years, an increasing number of articles were published regarding TMS research for the treatment of MDD, addiction, and dementia, which were among those most commonly investigated psychiatric disorders, whereas the number of articles addressing schizophrenia and OCD treated via TMS remained steady since 2015. Regarding TMS modalities, previous high-frequency stimulation, low-frequency stimulation, and bilateral stimulation were the most common topics, with research regarding deep TMS and theta burst stimulation having increased since 2000 and 2005, respectively. CONCLUSION: TMS applications are rapidly developing and becoming increasingly ubiquitous in various psychiatric disorders. Determining publication trends in TMS research can be a useful method for monitoring TMS research interests and applications of new TMS modalities for psychiatric disorders.
  • Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Masakazu Hatano, Nakao Iwata
    Molecular psychiatry 27(2) 1136-1144 2021年10月12日  査読有り
    A systematic review and random-effects model network meta-analysis was conducted to compare the efficacy, acceptability, tolerability, and safety of pharmacological interventions for adults with acute bipolar mania. We searched PubMed, the Cochrane Library, and Embase databases for eligible studies published before March 14, 2021. Randomized controlled trials (RCTs) of oral medication monotherapy lasting ≥10 days in adults with mania were included, and studies that allowed the use of antipsychotics as a rescue medication during a trial were excluded. The primary outcomes were response to treatment (efficacy) and all-cause discontinuation (acceptability). The secondary outcomes were the improvement of mania symptoms and discontinuation due to inefficacy. Of the 79 eligible RCTs, 72 double-blind RCTs of 23 drugs and a placebo were included in the meta-analysis (mean study duration = 3.96 ± 2.39 weeks, n = 16442, mean age = 39.55 years, with 50.93% males). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed response to treatment (N = 56, n = 14503); aripiprazole, olanzapine, quetiapine, and risperidone had lower all-cause discontinuation; however, topiramate had higher all-cause discontinuation (N = 70, n = 16324). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed the improvement of mania symptoms (N = 61, n = 15466), and aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, valproate, and ziprasidone had lower discontinuation due to inefficacy (N = 50, n = 14284). In conclusions, these antipsychotics, carbamazepine, lithium, tamoxifen, and valproate were effective for acute mania. However, only aripiprazole, olanzapine, quetiapine, and risperidone had better acceptability than the placebo.
  • Neuropsychopharmacology reports 41(3) 266-324 2021年8月12日  査読有り
  • Yuki Matsuda, Ryuichi Yamazaki, Taro Kishi, Nakao Iwata, Masahiro Shigeta, Shinsuke Kito
    Neuropsychobiology 1-9 2021年7月28日  査読有り筆頭著者責任著者
    INTRODUCTION: Repetitive transcranial magnetic stimulation (rTMS) has been employed worldwide for therapy-resistant depression. The Food and Drug Administration has approved a number of therapeutic devices for treating major depressive disorder; however, no studies have examined the differences in efficacy and acceptability among commercially available stimulation devices. The aim of our study was to compare the efficacy and acceptability of 3 stimulation devices (NeuroStar, MagPro, and Magstim) for depressive disorders. METHODS: Our study included 31 randomized sham-controlled trials of high-frequency rTMS included in the network meta-analysis by Brunoni. We calculated the risk ratio and 95% confidence intervals, comparing each device with sham for the endpoints of response rate, remission rate, and all-cause discontinuation. We then analyzed the differences among the devices in effect size for those endpoints. RESULTS: After determining the effect sizes for the endpoints, we found no statistically significant subgroup differences in the response rates, all-cause discontinuation, or remission rates among the devices (p = 0.12, p = 0.84, and p = 0.07, respectively). CONCLUSION: Our results suggest similar efficacy and acceptability for the 3 stimulation devices. Future studies need to perform head-to-head comparisons of the efficacy and acceptability of the stimulation devices for treating depression using the same stimulation protocols.
  • Yuki Matsuda, Kodai Yamada, Rema Terada, Ryuichi Yamazaki, Akihiko Nunomura, Masahiro Shigeta, Shinsuke Kito
    Asian journal of psychiatry 62 102737-102737 2021年6月6日  査読有り筆頭著者責任著者
  • Nagisa Katayama, Keisuke Inamura, Ryuichi Yamazaki, Yuki Matsuda, Akihiko Nunomura, Masahiro Shigeta
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 21(4) 675-677 2021年4月19日  査読有り
  • Ryuichi Yamazaki, Hiroyuki Ohbe, Yuki Matsuda, Shinsuke Kito, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
    The journal of ECT 37(3) 176-181 2021年4月9日  査読有り
    OBJECTIVES: This study aimed to evaluate whether early electroconvulsive therapy (ECT) can reduce length of hospital stay and total hospitalization costs in major depressive disorder (MDD) patients. METHODS: Using the Japanese Diagnosis Procedure Combination inpatient database from April 2011 to March 2018 linked with the Annual Report for Functions of Medical Institutions, we identified patients admitted for MDD. Patients who received ECT within 8 days of admission were assigned to the early ECT group and the remaining patients to the control group. The primary outcomes were length of hospital stay and total hospitalization costs. The secondary outcomes were in-hospital mortality and fatal adverse events. Propensity score-matched analyses were performed to compare the outcomes between the 2 groups. RESULTS: We identified 41,248 eligible patients, comprising 1169 in the early ECT group and 40,079 in the control group. After 1:1 propensity score matching, patients in the early ECT group had significantly shorter length of hospital stay than those in the control group (difference: -12.6 days; 95% confidence interval: -17.4 to -7.7 days). There was no significant difference in total hospitalization costs between the 2 groups. Early ECT was not significantly associated with increased in-hospital mortality or fatal adverse events. CONCLUSIONS: Early ECT may reduce length of hospital stay without increasing total hospitalization costs or fatal adverse events in patients with MDD.
  • Yuki Matsuda, Rema Terada, Kodai Yamada, Ryuichi Yamazaki, Akihiko Nunomura, Masahiro Shigeta, Shinsuke Kito
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 21(4) 681-682 2021年4月5日  査読有り筆頭著者責任著者
  • Taro Kishi, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Kazuo Mishima, Nakao Iwata
    Psychological medicine 51(15) 1-1 2021年3月24日  
  • Taro Kishi, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Satoru Esumi, Yasuhiko Hashimoto, Masakazu Hatano, Nobumi Miyake, Itaru Miura, Kazuo Mishima, Nakao Iwata
    Bipolar disorders 23(8) 789-800 2021年2月9日  査読有り
    OBJECTIVES: A systematic review and meta-analysis of double-blind, randomized placebo-controlled trials were conducted to examine how soon an increase in recurrence risk could be observed among bipolar I disorder (BDI) patients who were clinically stable with the combination therapy of mood stabilizers with second-generation antipsychotics (SGA+MS) treatment following second-generation antipsychotics discontinuation (i.e., MS alone) compared with SGA+MS maintenance. METHODS: Embase, PubMed, and CENTRAL databases were used for systematic literature searches until May/22/2020. The primary outcome was the recurrence rate of any mood episode at 6 months. The secondary outcomes were the recurrence rates of manic/hypomanic/mixed and depressive episodes and all-cause discontinuation at 6 months. The recurrence rates at 1, 2, 3, 9, and 12 months were also investigated. RESULTS: Eight studies (mean study duration = 58.25 ± 33.63 weeks) were identified (SGA+MS group [n = 1,456: 3 aripiprazole+MS studies, 1 lurasidone+MS study, 1 olanzapine+MS study, 2 quetiapine+MS studies, 1 ziprasidone+MS study] and placebo+MS group [n = 1,476]). Pooled SGA+MS exhibited lower recurrence rates of any mood episode, manic/hypomanic/mixed episodes, and depressive episodes as well as reduced all-cause discontinuation at every observational point. The risk ratios (95% confidence interval) of the recurrence rate at 6 months were 0.51 (0.39-0.86) for any mood episode, 0.42 (0.30-0.59) for manic/hypomanic/mixed episodes, and 0.39 (0.28-0.54) for depressive episodes. The RR for all-cause discontinuation was 0.67 (0.50-0.89). Both aripiprazole+MS and quetiapine+MS outperformed placebo+MS in the recurrence of any mood, manic/hypomanic/mixed, and depressive episodes at 6 months. CONCLUSIONS: SGA+MS prevented recurrence for up to 12 months for BDI compared with placebo+MS.
  • Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Kazuo Mishima, Nakao Iwata
    Molecular psychiatry 26(8) 4146-4157 2020年11月11日  査読有り
    We searched Embase, PubMed, and CENTRAL from inception until 22 May 2020 to investigate which antipsychotics and/or mood stabilizers are better for patients with bipolar disorder in the maintenance phase. We performed two categorical network meta-analyses. The first included monotherapy studies and studies in which the two drugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placebo). The second included studies on second-generation antipsychotic combination therapies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compared with placebo with LIT/VAL. Outcomes were recurrence/relapse rate of any mood episode (RR-any, primary), depressive episode (RR-dep) and manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual adverse events. Risk ratios and 95% credible interval were calculated. Forty-one randomized controlled trials were identified (n = 9821; mean study duration, 70.5 ± 36.6 weeks; percent female, 54.1%; mean age, 40.7 years). All active treatments other than carbamazepine, lamotrigine+valproate (no data) and paliperidone outperformed the placebo for RR-any. Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapine outperformed placebo for RR-dep. All active treatments, other than aripiprazole+valproate, carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed placebo for RR-mania. Asenapine, lithium, olanzapine, quetiapine, and valproate outperformed placebo for all-cause discontinuation. All SGAs+LIT/VALs other than olanzapine+LIT/VAL outperformed placebo+LIT/VAL for RR-any. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-dep. Aripiprazole+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-mania. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for all-cause discontinuation. Treatment efficacy, tolerability, and safety profiles differed among treatments.
  • Taro Kishi, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Kazuo Mishima, Nakao Iwata
    Psychological medicine 51(15) 1-9 2020年10月13日  査読有り
    BACKGROUND: This random-effects model meta-analysis of double-blind, randomized placebo-controlled trials compared recurrence rates in bipolar disorder (BD) patients between antipsychotic/mood stabilizer discontinuation and maintenance groups. METHODS: We conducted systematic literature search of Embase, PubMed, and CENTRAL databases without language restriction from inception until 22 May 2020. Independent investigators assessed studies and extracted data. We calculated risk ratios (RRs) and numbers needed to benefit or harm (NNTB/NNTH). Primary outcome was the recurrence rate of any mood episode at 6 months. Secondary outcomes were recurrence rates of depressive episodes and manic/hypomanic/mixed episodes and all-cause discontinuation at 6 months. We also investigated these outcomes at 1, 3, 9, 12, 18, and 24 months. RESULTS: We identified 22 studies (n = 5462) receiving aripiprazole, asenapine, divalproex, long-acting injectable (LAI)-aripiprazole, LAI-risperidone, lamotrigine, lithium, olanzapine, paliperidone, or quetiapine. Mean study duration was 64.50 ± 69.35 weeks. The maintenance group demonstrated lower recurrence rates of any mood episode, depressive episodes, and manic/hypomanic/mixed episodes as well as reduced all-cause discontinuation at every observational point. The RRs (95% confidence interval, NNTB/NNTH) of recurrence rate at 6 months were 0.61 (0.54-0.70, 5) for any mood episode, 0.72 (0.60-0.87, 13) for depressive episodes, and 0.45 (0.36-0.57, 6) for manic/hypomanic/mixed episodes. The RR for all-cause discontinuation at 6 months was 0.71 (0.61-0.82, 6). CONCLUSIONS: Maintaining drug treatment during clinically stable BD prevented recurrence for up to 24 months. Discontinuation of medications for ⩾1 month significantly increased recurrence risk. However, 47.3% of patients who discontinued drugs for 6 months did not experience recurrence.
  • Taro Kishi, Ikuo Nomura, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Toshikazu Ikuta, Nakao Iwata
    Journal of psychiatric research 128 68-74 2020年9月  査読有り
    We conducted a random-effects model network meta-analysis to examine differences between lemborexant and suvorexant in efficacy and safety outcomes for treating patients with insomnia. We searched Embase, MEDLINE, and CENTRAL from their inception until April/28/2020. Primary outcomes were subjective time to sleep onset (sTSO), subjective total sleep time (sTST), and subjective wake-after-sleep onset (sWASO) at week 1. Four double-blind, randomized controlled trials were identified (n = 3237; 72.4% female; mean age 58.0 years). The treatment arm consisted of lemborexant 10 mg/d (LEM10, n = 592), lemborexant 5 mg/d (LEM5, n = 589), suvorexant 20/15 mg/d (SUV20/15, n = 493), zolpidem tartrate extended release 6.25 mg/d (ZOL6.25, n = 263), and placebo (n = 1300). All active treatments outperformed placebo regarding sTSO at week 1; standardized mean differences (95% credible interval): LEM10 = -0.51 (-0.63, -0.39), LEM5 = -0.48 (-0.60, -0.36), SUV20/15 = -0.21 (-0.33, -0.10), and ZOL6.25 = -0.30 (-0.46, -0.14); sTST at week 1: LEM10 = -0.58 (-0.70, -0.45), LEM5 = -0.33 (-0.46, -0.21), SUV20/15 = -0.34 (-0.46, -0.23), and ZOL6.25 = -0.42 (-0.59, -0.25); and sWASO at week 1: LEM10 = -0.42 (-0.57, -0.28), LEM5 = -0.26 (-0.40, -0.11), SUV20/15 = -0.18 (-0.32, -0.05), and ZOL6.25 = -0.37 (-0.56, -0.18). Although no significant differences were found in discontinuation due to adverse events between each active drug and placebo, LEM10 and SUV20/15 were associated with greater somnolence compared with placebo. LEM10 had the largest effect size compared with placebo for all primary outcomes, although with a risk of somnolence.
  • Taro Kishi, Yuki Matsuda, Kenji Sakuma, Makoto Okuya, Nakao Iwata
    Journal of psychiatric research 130 240-246 2020年8月15日  査読有り
    This study investigated factors associated with discontinuation in double-blind, randomized, placebo-controlled trials (DBRPCTs) of second-generation antipsychotics (SGAs) for acute schizophrenia, with a view to establishing what factors were associated with all-cause discontinuation. 77 eligible studies (96 comparisons; n = 22,678) were included in this study. Thirty-one factors potentially affecting all-cause discontinuation, related to the participants, study design, and drugs, were included in a meta-regression analysis that examined the factors associated with discontinuation rates in treatment and placebo groups and/or the treatment-placebo group difference in discontinuation. Smaller improvements in Positive and Negative Syndrome Scale total scores from baseline to endpoint were associated with higher discontinuation rates in both the treatment and placebo groups, and smaller response rates in the treatment group were associated with higher discontinuation rates in the treatment group. These factors were also associated with the treatment-placebo group difference in discontinuation. Although the risk of weight gain from SGA use was not associated with discontinuation rates in either the treatment or placebo groups, SGAs with a risk of weight gain were associated with a larger treatment-placebo group difference in discontinuation, although the reason is unknown. Factors associated with discontinuation rates in both treatment and placebo groups did not influence the treatment-placebo group difference in discontinuation. The efficacy and the risk of weight gain of SGAs seemed to influence treatment-placebo group difference in discontinuation in DBRPCTs of SGAs for acute schizophrenia.
  • Taro Kishi, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Satoru Esumi, Yasuhiko Hashimoto, Masakazu Hatano, Nobumi Miyake, Itaru Miura, Kengo Miyahara, Kiyoshi Fujita, Kunihiro Kawashima, Kazuo Mishima, Nakao Iwata
    Journal of clinical psychopharmacology 40(5) 468-474 2020年7月22日  査読有り
    BACKGROUND: The exact recurrence rate of bipolar disorder in patients receiving lithium maintenance phase treatment and the modifiers associated with recurrence are still unknown. METHODS: We searched Embase, PubMed, and CENTRAL from inception until April 28, 2020. Outcomes included recurrence rate of any mood episode, depressive episodes, and manic/hypomanic/mixed episodes; all-cause discontinuation rate; and discontinuation rate due to adverse events. A random-effects model, single-group summary meta-analysis was conducted. A meta-regression analysis to examine whether the modifiers (total number of patients, %female, mean age, duration of study, duration of preliminary phase, publication year, bipolar disorder type, mood status at recruitment, presence of a placebo arm, sponsorship, enrichment design, number of treatment arms, and risk of bias for blinding or randomization) were associated with the event rate of the outcomes was also performed. RESULTS: We identified 21 randomized trials (n = 1,415; mean study duration, 78.40 ± 32.10 weeks; %female, 54.85%; mean age, 43.47 ± 4.88 years). The event rates (95% confidence interval [CI]) were as follows: recurrence of any mood episode, 39.8% (32.8%, 47.1%); depressive episodes, 25.6% (18.8%, 34.0%); manic/hypomanic/mixed episodes, 18.5% (13.7%, 24.7%); all-cause discontinuation rate, 67.0% (57.2%, 75.5%); and discontinuation rate due to adverse events, 8.7% (5.1%, 14.7%). After adjusting for multiple testing, our meta-regression analysis showed association only between the all-cause discontinuation rate and presence of a placebo arm. CONCLUSIONS: The recurrence rate of depressive episodes seemed to be higher than the recurrence rate of manic/hypomanic/mixed episodes. The all-cause discontinuation rate was high. However, the studies included in our meta-analysis were of short duration.
  • Hiroshi Kameyama, Kenichi Sugimoto, Keisuke Inamura, Kyoko Itoh, Fumitoshi Kodaka, Yuki Matsuda, Kazutaka Nukariya, Tomohiro Kato, Masahiro Shigeta
    2020年7月17日  
    <title>Abstract</title><sec><title>Introduction</title>Recent studies have shown a high frequency of abnormal electrocardiograms in patients with schizophrenia. The objective of this study was to associate schizophrenia diagnoses with early repolarization patterns in a sample of hospitalized patients from a single hospital in Japan. </sec><sec><title>Methods</title>We conducted a retrospective age, sex and coronary risk factors matched case-control study on 85 patients with schizophrenia and 89 controls from medical checkups. First, we compared the presence of early repolarization patterns in both groups. Secondly, we elucidated an association between the presence of an early repolarization pattern and clinical findings in the patients’ groups. We also evaluated J-point elevation patterns. </sec><sec><title>Results</title>As a result, we found that both early repolarization patterns and J-point elevation patterns observed were significantly higher in the schizophrenic group than in the matched control group (early repolarization pattern 23;6 P &lt; 0.001; J-point elevation pattern 34:12; P = 0.001). After multivariable logistic regression among the patients and controls, schizophrenia was the independent predictor for early repolarization pattern (P = 0.001) and J-point elevation (P &lt; 0.001). Among the patients, the independent predictor for early repolarization pattern was psychiatric family history (P = 0.006), while older age (P = 0.038) and psychiatric family history (P = 0.014) were predictors for J-point elevation patterns. </sec><sec><title>Conclusion</title>These findings suggest that an association between early repolarization pattern or J-point elevation pattern and schizophrenia in a single Japanese center. </sec>
  • Ryuichi Yamazaki, Shinsuke Kito, Yuki Matsuda, Masahiro Shigeta
    Psychiatry and clinical neurosciences 74(6) 372-373 2020年3月20日  査読有り
  • Taro Kishi, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Nakao Iwata
    Psychiatry and clinical neurosciences 74(5) 330-332 2020年3月16日  査読有り
  • Taro Kishi, Reiji Yoshimura, Yuki Matsuda, Kenji Sakuma, Nakao Iwata
    Pharmacopsychiatry 53(3) 122-132 2020年1月30日  査読有り
    INTRODUCTION: The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics. METHODS: The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6). RESULTS: All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges' g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were-0.40 (-0.58,-0.22),-0.61 (-0.79,-0.42),-0.33 (-0.60,-0.07), and-0.69 (-0.93,-0.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events. DISCUSSION: BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia.
  • Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Nakao Iwata
    Psychopharmacology 237(5) 1459-1470 2020年1月30日  査読有り
    RATIONALE: What is the difference between aripiprazole and brexpiprazole? OBJECTIVES: This systematic review, network meta-analysis of randomized trials evaluated the efficacy and safety/tolerability of aripiprazole and brexpiprazole for treating acute schizophrenia. METHODS: We searched Scopus, MEDLINE, and Cochrane Library from inception until May 22, 2019. The response rate was set as the primary outcome. Other outcomes were discontinuation rate and incidence of individual adverse events. The risk ratio (RR) and 95% credible interval (95%CrI) were calculated. RESULTS: Fourteen studies were identified (n = 3925). Response rates of both aripiprazole and brexpiprazole were superior to that of the placebo (RR [95%CrI]: aripiprazole = 0.84 [0.78, 0.92], brexpiprazole = 0.84 [0.77, 0.92]). Aripiprazole and brexpiprazole were associated with a lower incidence of all-cause discontinuation (0.80 [0.71, 0.89], 0.83 [0.72, 0.95]), adverse events (0.67 [0.47, 0.97], 0.64 [0.46, 0.94]), and inefficacy (0.56 [0.40, 0.77], 0.68 [0.48, 0.99]) compared with the placebo. Although brexpiprazole was associated with a lower incidence of schizophrenia as an adverse event compared with the placebo (0.57 [0.37, 0.85]), aripiprazole and brexpiprazole were associated with a higher incidence of weight gain compared with the placebo (2.12 [1.28, 3.68], 2.14 [1.35, 3.42]). No significant differences were found in other individual adverse events, such as somnolence, akathisia, extrapyramidal symptoms, and dizziness between aripiprazole or brexpiprazole and placebo. Any outcome between aripiprazole and brexpiprazole were not different. CONCLUSIONS: Differences in short-term efficacy and safety for acute schizophrenia were not apparent between aripiprazole and brexpiprazole. Future studies are warranted to evaluate whether there are differences in the long-term outcome between treatments.
  • Yuki Matsuda, Yujiro Furukawa, Ryuichi Yamazaki, Keisuke Inamura, Shinsuke Kito, Akihiko Nunomura, Masahiro Shigeta
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 20(4) 536-537 2020年1月23日  査読有り筆頭著者責任著者
  • Yuki Matsuda, Shinsuke Kito, Yoshio Igarashi, Masahiro Shigeta
    Neuropsychobiology 79(3) 1-6 2020年1月17日  査読有り筆頭著者責任著者
    OBJECTIVES: Major depression is a highly prevalent disorder that causes economic burden in office workers. We conducted a randomized, double-blind, sham-controlled trial to evaluate the efficacy and safety of deep transcranial magnetic stimulation (dTMS) in office workers with treatment-resistant depression. METHODS: In this study, we randomized office workers taking administrative leave for treatment-resistant major depressive disorder or bipolar disorder with current major depressive episode. dTMS treatment was applied at 120% resting motor threshold with 18 Hz over the left dorsolateral prefrontal cortex. The treatment sessions delivered a total of 1,980 pulses a day, 5 days a week, for 4-6 weeks. The primary outcome was change in the total score on the 21-item Hamilton Depression Rating Scale (HDRS-21) from baseline to the end of study in an intent-to-treat analysis. The secondary outcomes were the response and remission rates. We also assessed changes in cognitive function and adverse events. RESULTS: Forty patients were randomized to active or sham dTMS groups (1:1). The change in the total score on the HDRS-21 was more significantly improved in the active group than in the sham group at 6 weeks (p = 0.045). There were no significant differences in the response and remission rates or cognitive measures between the active and sham groups. No serious adverse events were observed in either group. CONCLUSIONS: These results suggest that dTMS might be effective and safe in office workers with treatment-resistant depression. Further well-designed studies are needed.
  • Taro Kishi, Kenji Sakuma, Ikuo Nomura, Yuki Matsuda, Kazuo Mishima, Nakao Iwata
    The international journal of neuropsychopharmacology 22(11) 698-709 2019年11月1日  査読有り
    BACKGROUND: This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5-3 mg/d) for major depressive disorder where antidepressant treatment had failed. METHODS: The outcomes were the response rate (primary), remission rate (secondary), Montgomery Åsberg Depression Rating Scale score (secondary), Sheehan Disability Scale scores (secondary), Clinical Global Impression-Improvement/Severity scores, discontinuation rate, and individual adverse events. A subgroup meta-analysis of the data at week 6 compared outcomes by dose >2 mg/d or ≤2 mg/d (2 mg/d is the recommended dose). RESULTS: We identified 9 studies (n = 3391). Compared with placebo, brexpiprazole (any dose) was superior for response rate (risk ratio [RR] = 0.93, 95% confidence interval [95% CI] = 0.89-0.97, number needed to treat = 17), remission rate (RR = 0.95, 95% CI = 0.93-0.98, number needed to treat = 25), Montgomery Åsberg Depression Rating Scale score (standardized mean difference = -0.20, 95% CI = -0.29, -0.11), Sheehan Disability Scale score (standardized mean difference = -0.12, 95% CI = -0.21, -0.04), and Clinical Global Impression-Improvement/Severity scores but was associated with a higher discontinuation rate, akathisia, insomnia, restlessness, somnolence, and weight increase. Doses >2 mg/d had a significantly higher RR for response rate than ≤2 mg/d (0.96 vs 0.89); moreover, compared with placebo, doses >2 mg/d were associated with higher incidences of akathisia (RR = 4.58) and somnolence (RR = 7.56) as well as were marginally associated with a higher incidence of weight increase (RR = 3.14, P = .06). Compared with placebo, doses ≤2 mg/d were associated with higher incidences of akathisia (RR = 2.28) and weight increase (RR = 4.50). CONCLUSIONS: Brexpiprazole adjunctive treatment is effective for major depressive disorder when antidepressant treatment fails. At 6 weeks, doses ≤2 mg/d presented a better risk/benefit balance than >2 mg/d.
  • Kazuto Oya, Kenji Sakuma, Satoru Esumi, Yasuhiko Hashimoto, Masakazu Hatano, Yuki Matsuda, Yuki Matsui, Nobumi Miyake, Ikuo Nomura, Makoto Okuya, Nakao Iwata, Masaki Kato, Ryota Hashimoto, Kazuo Mishima, Norio Watanabe, Taro Kishi
    Neuropsychopharmacology reports 39(3) 241-246 2019年9月  査読有り
    AIM: Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully. This systematic review and meta-analysis evaluated the efficacy and safety of lithium and lamotrigine for maintenance treatment in clinically stable patients with adult BD. METHODS: This meta-analysis included only double-blind, randomized, placebo-controlled trials with an enrichment design that selected patients who responded acutely to lithium or lamotrigine. Reports prior to November 15, 2018, were retrieved from the PubMed/Cochrane Library/Embase. The primary outcome was the relapse rate due to any mood episode at the study endpoint. Other outcomes were relapse rates due to a manic/hypomanic/mixed episode or depression at the study endpoint, discontinuation rate, death, and death by suicide. Risk ratios (RRs) (95% confidence intervals) were calculated. When the random-effects model showed significant differences between groups, the number-needed-to-treat (NNT) was estimated. RESULTS: The search retrieved two studies regarding lithium (N = 218) and four evaluating lamotrigine (N = 706). Both drugs were superior to placebo for reducing the relapse rate due to any mood episode [lithium: RR = 0.52 (0.41-0.66), P < 0.00001, I2  = 0%, NNT = 2.3 (1.6-4.2); lamotrigine: RR = 0.81 (0.70-0.93), P = 0.004, I2  = 0%, NNT = 8.3 (5.0-25.0)] and all-cause discontinuation. There were no significant differences in other outcomes between lithium or lamotrigine and the placebo groups. CONCLUSION: Both drugs showed benefit for preventing relapse in clinically stable patients with adult BD. However, the number of studies and patients in this analysis was small.
  • Shinsuke Kito, Midori Miyazi, Honoka Nakatani, Yuki Matsuda, Ryuichi Yamazaki, Tatsuya Okamoto, Yoshio Igarashi
    Neuropsychopharmacology reports 39(3) 203-208 2019年9月  査読有り
    AIM: Clinical trials and meta-analyses have demonstrated the efficacy of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left prefrontal cortex in treatment-resistant depression. The aim of this study was to prospectively evaluate the effectiveness of the conventional 37.5-minute vs 18.75-minute rTMS protocol over the left prefrontal cortex in patients with treatment-resistant depressive episode. METHODS: Thirty patients with treatment-resistant depression or bipolar disorder depressive episode were randomized 1:1 to either 37.5-minute or 18.75-minute rTMS protocol groups. rTMS treatment was applied at 120% resting motor threshold with 10 Hz over the left prefrontal cortex. Treatment sessions were delivered for a total of 3000 pulses/d, 5 days a week, for 4-6 weeks. Patients received a 75 trains with "4 sec on and 26 sec off" for 37.5 minutes or a 75 trains with "4 sec on and 11 sec off" for 18.75 minutes. Severity of depression was rated with the Quick Inventory of Depressive Symptomatology (QIDS) and Patient Health Questionnaire (PHQ-9). Remission was defined as a total score of 5 or less on the QIDS. The primary outcome measure was to compare the remission rate between the both groups. RESULTS: Thirteen of 30 patients (43.3%) showed remission at week 6. There were no significant differences in the remission rate between the conventional 37.5- and 18.75-minute protocol groups (46.7% and 40.0%, respectively). No seizures or treatment-emergent mania/hypomania were occurred. CONCLUSION: These findings suggest that, compared with the conventional one, rTMS with 18.75-minute protocol might be equally effective and clinically beneficial in saving the treatment session length. Further well-designed studies are needed.
  • Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Nakao Iwata
    Neuropsychopharmacology reports 39(3) 256-259 2019年9月  査読有り
    OBJECTIVE: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. METHODS: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. RESULTS: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = -0.488; 95% CrI = -0.881, -0.089) and blood prolactin levels (SMD = -0.642; 95% CrI = -1.073, -0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = -0.408; 95% CrI = -0.785, -0.030) than QUEXR300. CONCLUSION: Although the two drugs' efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.
  • Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Yuki Matsuda, Nakao Iwata
    Journal of psychiatric research 115 121-128 2019年8月  査読有り
    This study evaluated the efficacy and safety/tolerability of quetiapine extended-release 300 mg/day (QUEXR300), quetiapine immediate-release 600 mg/day (QUEIR600), and quetiapine immediate-release 300 mg/day (QUEIR300) formulations for treating bipolar depression. A random-effect network meta-analysis of 8-week, double-blind, randomized placebo-controlled trials was used to determine the most optimal agent for intervention. Remission rate was set as the primary outcome. Secondary outcomes were response rate, improvement in the Montgomery-Åsberg Depression Rating Scale score, discontinuation rate, and the incidence of individual adverse events. Seven eligible studies including 3267 participants were included in the meta-analysis. The QUEIR600, QUEIR300, and QUEXR300 groups were superior to the placebo group in every efficacy outcome; however, there were no significant differences in the efficacy outcomes among the treatment groups. All treatment groups exhibited higher incidences of extrapyramidal symptoms, dry mouth, somnolence, constipation, and increase in body weight than the placebo group. The QUEIR600 and QUEIR300 groups had higher incidences of dizziness than the placebo group. The QUEIR600 group had a higher discontinuation rate due to adverse events than the placebo group, and the QUEIR300 group had higher blood HbA1c levels than the placebo group. The QUEIR600 and QUEXR300 groups had higher incidences of ≥7% weight gain than the placebo group. The QUEXR300 group had a higher incidence of fatigue than the QURIR300 and placebo groups. In conclusion, there were no significant differences in the efficacies of QUEIR600, QUEIR300, and QUEXR300 in treating bipolar depression; moreover, tolerance to QUEIR600 might be worse than the other treatments.
  • Taro Kishi, Toshikazu Ikuta, Yuki Matsui, Ken Inada, Yuki Matsuda, Kazuo Mishima, Nakao Iwata
    Psychological medicine 49(5) 772-779 2019年4月  査読有り
    BACKGROUND: Discontinuation of antipsychotics predisposes patients with remitted/stable first-episode psychosis (FEP) to a higher risk of relapse, but it remains unclear how long discontinuation increases the relapse rate in these patients compared with maintenance. METHODS: This meta-analysis of randomized controlled trials (RCTs) compared relapse rates in FEP patients between antipsychotic treatment discontinuation and maintenance groups at 1, 2, 3, 6, 9, 12 (primary), and 18-24 months. The risk ratio (RR) and numbers needed to treat/harm (NNT/NNH) were calculated using a random-effects model. RESULTS: Ten RCTs were identified (n = 776; mean study duration, 18.6 ± 6.0 months). The antipsychotics were discontinued abruptly in four RCTs (which reported data only at 12 months) and after tapering off gradually over several months (mean length, 3 months) in six RCTs. Compared with the discontinuation group, the maintenance group experienced significantly fewer relapses at all time points except 1 month [RR (NNT): 2 months, 0.49 (13); 3 months, 0.46 (9); 6 months, 0.55 (6); 9 months, 0.48 (3); 12 months, 0.47 (3); and 18-24 months, 0.57 (4)]. The maintenance group was associated with higher discontinuation due to adverse events (RR, 2.61; NNH, not significant). CONCLUSIONS: Maintaining antipsychotic treatment prevented relapse for up to 24 months in FEP patients. Discontinuation of antipsychotics for ⩾2 months significantly increased the risk of relapse. However, 45.7% of patients who discontinued antipsychotics for 12 months (39.4% after 18-24 months) did not experience a relapse.
  • Taro Kishi, Yuki Matsui, Yuki Matsuda, Asuka Katsuki, Hikaru Hori, Hiroko Yanagimoto, Kenji Sanada, Kiichiro Morita, Reiji Yoshimura, Yoshihisa Shoji, Katsuhiko Hagi, Nakao Iwata
    Pharmacopsychiatry 52(2) 52-62 2019年2月  査読有り
    INTRODUCTION: We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). METHODS: Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. RESULTS: Ten RCTs (n=1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD=-10.62, 95% CI=-17.67 to -3.560, p=0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR=1.373, 95% CI=1.088-1.734, p=0.008, NNH=11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. DISCUSSION: The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
  • Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N
    The international journal of neuropsychopharmacology 21(8) 748-757 2018年5月  査読有り

主要なMISC

 100
  • 髙橋隼, 松田勇紀, 鬼頭伸輔, 中村元昭, 伊津野拓司, 野田賀大
    精神神経学雑誌 126(9) 589-598 2024年9月  
  • 垂石 七星, 松田 勇紀, 鬼頭 伸輔
    臨床精神薬理 27(7) 691-698 2024年7月  
    神経可塑性仮説はうつ病の病態仮説の一つであり,神経系が経験に基づいてその構造や機能を変化させ,特定のシナプスを選択的に強化する性質のことである。神経可塑性は複雑な分子学的メカニズムで制御されており,その障害はうつ病の発症に関連しているとされている。反復経頭蓋磁気刺激(rTMS)療法は治療抵抗性うつ病に対して神経可塑性を調節して抗うつ効果をもたらし,ベンゾジアゼピン系薬剤やN-メチル-D-アスパラギン酸受容体部分作動薬などの薬剤との併用によって抗うつ効果が変化することが臨床試験で示されている。また,rTMS療法は治療時間の長さが課題となっていたが,間欠的シータバースト刺激(iTBS),加速iTBS,Stanford Neuromodulation Therapyなどの治療時間を大幅に短縮し,高い治療効果をもたらす新規プロトコルが開発されている。(著者抄録)
  • 都留京子, 松田勇紀
    精神科Resident 2(4) 249-252 2021年  
    <Key Point>・初発精神病性障害には多数の診断が鑑別にあげられ、治療開始時に診断確定は困難だが、統合失調症を念頭に置いてすみやかに薬物療法および心理社会的支援を開始する必要がある・初期治療における薬剤選択は第二世代抗精神病薬(SGAs)が推奨されており、副作用やアドヒアランスに配慮して個別に選択することが求められる・維持療法は再発予防の観点から長期間の抗精神病薬継続が必要だが、期間についての一致した見解は得られておらず、患者および家族が中止を希望した場合は、再発のリスクを十分に話し合い慎重に決定するべきである(著者抄録)
  • 岸太郎, 江角悟, 大矢一登, 奥谷理, 佐久間健二, 野村郁雄, 橋本保彦, 波多野正和, 波多野正和, 松井佑樹, 松田勇紀, 三宅誕実, 三島和夫, 岩田仲生
    臨床精神薬理 24(9) 937-942 2021年  
    私達は以下の2つの臨床疑問を立てた。臨床疑問1:リチウム単剤療法により臨床的に安定した成人双極性障害患者に対し、リチウムの継続は、その中止に比し、推奨できるか?臨床疑問1に対する推奨文:リチウム単剤治療で臨床的に安定した成人双極性障害患者に対して、リチウムの継続は、2年に限り強く推奨される。今後、更に長期的なリチウム維持療法の有用性に関して検討する必要がある。臨床疑問2:ラモトリギン単剤療法により臨床的に安定した成人双極性障害患者に対し、ラモトリギンの継続は、その中止に比し、推奨できるか?臨床疑問2に対する推奨文:ラモトリギン単剤治療で臨床的に安定した成人双極性障害患者に対して、ラモトリギンの継続は、0.5~1.5年に限り弱く推奨される。今後、更に長期的なラモトリギン維持療法の有用性に関して検討する必要がある。(著者抄録)
  • 都留 京子, 松田 勇紀, 鬼頭 伸輔
    精神科Resident 1(1) 29-31 2020年10月  
    <Key Point>・rTMS療法は、わが国で2019年6月から、成人の薬物療法に反応しない治療抵抗性うつ病に対して保険診療が開始された新たな治療法である・薬物療法の併用下で治療抵抗性うつ病に対するrTMS療法の寛解率は30〜40%である・rTMS療法では頭痛、刺激部位の疼痛・不快感、筋収縮などの副作用がある。まれにけいれん発作が生じる(著者抄録)
  • 松田 勇紀, 鬼頭 伸輔
    老年精神医学雑誌 29(12) 1266-1272 2018年12月  
    日本では急速に高齢化が進み、老年期うつ病が増加している。老年期うつ病患者は若年うつ病患者と比較して、抗うつ薬に対する治療反応性が乏しい。さらに、再発・再燃しやすく、自殺率も高い。老年期うつ病への反復経頭蓋磁気刺激(rTMS)療法の有効性について一致した見解は得られていなかったが、最近の臨床研究の結果から、現在の標準的な刺激条件で実施すれば十分な治療効果が期待できると考えられる。今後、老年期うつ病に対するrTMS療法の検証的試験が待たれる。(著者抄録)
  • 松田 勇紀, 鬼頭 伸輔
    臨床精神医学 47(8) 861-867 2018年8月  
  • 松田 勇紀, 鬼頭 伸輔
    精神医学 60(1) 91-97 2018年1月  
    うつ病は,前頭前野と辺縁系領域の活動の機能的不均衡が病態に関与している。左前頭前野への高頻度rTMSは,前頭前野の低活動,辺縁系の過活動を是正することが知られている。一方,神経ネットワークへの作用機序は明らかではない。本研究は,治療抵抗性うつ病に対して高頻度rTMSを施行し,その前後で安静時脳波を高密度脳波計で計測した。また,安静時脳波はsLORETAを用いて解析し,rTMSによる機能的結合の変化を調べた。結果は,左側背外側前頭前野と辺縁領域間のmiddle beta帯域を同調させ,GABA抑制系回路の修飾を行う可能性が考えられた。(著者抄録)
  • 三宅 誕実, 松田 勇紀, 岸 太郎
    臨床精神薬理 20(12) 1441-1447 2017年12月  
    初発精神病性障害は、精神病症状による著しい行動障害を初めて呈した状態である。本稿では、「統合失調症薬物治療ガイドライン」における初発精神病性障害への対応の特徴と実践的使用法を概説する。ガイドラインは、臨床疑問(clinical question:CQ)に答える形で作成されており、初発精神病性障害では4つのCQが設定されている。CQ1-1では初発精神病性障害患者に対して抗精神病薬を選択する際に参考となるエビデンス、CQ1-2では適切な用量について、CQ1-3では適切な治療効果判定期間について、CQ1-4では再発予防における治療継続期間についてそれぞれ検討し、推奨を述べている。ガイドラインの実践的使用法として、各CQの推奨の背景を理解し、薬物療法のリスクとベネフィットを十分患者と家族に説明した上で、共同作業的に医療行為を進めていくのが望ましい。(著者抄録)
  • 鬼頭 伸輔, 松田 勇紀, 長谷川 崇, 藤田 憲一
    機能的脳神経外科 56 15-22 2017年12月  
    反復経頭蓋磁気刺激(repetitive transcranial magnetic stimulation、rTMS)は、薬物療法に反応しないうつ病への有効性が示されており、わが国でも、2017年9月、新規治療法として承認された。2002年から2015年にかけて、著者らが行った臨床研究では、治療抵抗性うつ病患者に対して、左前頭前野への高頻度rTMS、右前頭前野への低頻度rTMS、それらを組み合わせた両側rTMSを実施した。その寛解率は、刺激条件によって異なるものの、約20〜40%であった。rTMSの抗うつ機序については、著者らの一連の神経画像研究は、高頻度rTMSが背外側前頭前野に促進的に作用し、低頻度rTMSが膝下部帯状回や前頭葉眼窩野などの腹内側前頭前野に抑制的に作用することで、rTMSが前頭前野と辺縁系領域の機能的不均衡を是正し、うつ病を改善させている可能性を示唆している。また、rTMSが、左背外側前頭前野と後部帯状回、左背外側前頭前野と辺縁系領域の機能的結合を修飾することも明らかにした。双極性うつ病への治療効果のある薬物療法は非常に限られている。著者らは、予備的研究として、ガイドラインが推奨する薬物療法に反応しない双極性うつ病患者に対して、右前頭前野への低頻度rTMSを行い、抑うつ症状だけではなく認知機能が改善することを報告した。今後、適切な研究デザインによる検証が俟たれる。(著者抄録)
  • 松田 勇紀, 山崎 龍一, 鬼頭 伸輔
    精神科治療学 32(10) 1339-1345 2017年10月  
    双極性うつ病に対する薬物療法の有効性は限定的であり、難治化する患者を経験する。反復経頭蓋磁気刺激(rTMS)は薬物療法に反応しない大うつ病性障害に対して、その有効性が確立されているが、双極性うつ病に対しては偽刺激を対照とした複数のランダム化試験が行われているものの、それらの結果は一致していない。一方、メタ解析では偽刺激群と比較して実刺激群は治療反応率が有意に優れ、サブグループ解析で右背外側前頭前野(DLPFC)が他の刺激部位より治療反応率が優れていた。既報の臨床試験の結果から、筆者らは薬物療法に反応しない双極性うつ病患者に対して右DLPFCへの低頻度刺激の予備的研究を行った。その結果は、抑うつ症状と認知機能の改善が示された。以上のことから、rTMSは難治の双極性うつ病患者への治療選択肢となる可能性が示唆された。今後、筆者らは偽刺激を対照とした二重盲検ランダム化試験を進める予定である。(著者抄録)
  • 松田 勇紀, 鬼頭 伸輔
    精神科治療学 32(4) 525-531 2017年4月  
    強迫症/強迫性障害(OCD)は若年で発症し、再発率は高く慢性化する患者が多い。また、OCDの治療は薬物療法や認知行動療法が行われているが、治療反応性に乏しく難治化しやすい。近年、治療抵抗性OCD患者に対して反復経頭蓋磁気刺激(rTMS)による治療が注目されている。OCD患者に対し、神経画像検査の知見から得られた病態仮説に基づき、右または左側の背外側前頭前野(DLPFC)に対して高頻度または低頻度刺激、前頭眼窩野(OFC)や補足運動野(SMA)に対して低頻度刺激が行われている。右または左側のDLPFCに対する高頻度または低頻度刺激を行った臨床研究は多く報告されているが、それらの結果は必ずしも一致せず、各研究間での異質性は大きかった。また、OFCに対する低頻度刺激は臨床研究が少なく、SMAに対する低頻度刺激は最近の臨床研究で結果は一致しなかった。よって、現時点では治療抵抗性OCDに対するrTMSの最適な刺激条件は明らかではないため、さらなる臨床研究が待たれる。(著者抄録)
  • 松田 勇紀, 鬼頭 伸輔
    臨床精神薬理 19(12) 1717-1723 2016年12月  
    日本では急速に高齢化が進み、高齢うつ病患者が増加している。高齢うつ病患者の特徴は、若年うつ病患者と比べて、抗うつ薬に対して効果が不十分な症例や、忍容性不良のため十分量の抗うつ薬を投与できない症例が多いことである。さらに抑うつ症状の再発・再燃症例も多いため、既存の治療では限界がある。そのため、現在までに様々な脳刺激療法の研究開発が行われている。脳刺激療法の中で、電気けいれん療法は高齢うつ病患者に対して、国内外で最も確立した治療法であり、なおかつその有効性は高い。しかし、認知障害の副作用が多く、高齢になるほど、認知障害が出現するリスクは増大する。一方で、反復経頭蓋磁気刺激や磁気けいれん療法は電気けいれん療法と比べて、認知障害の副作用は少なく、安全性の高い治療法と考えられている。しかし、高齢うつ病患者のみを対象とした臨床研究は少なく、最適な刺激パラメーターもわかっていないため、更なる臨床研究が必要である。(著者抄録)
  • 松田 勇紀, 岸 太郎, 岩田 仲生
    精神科 28(3) 185-190 2016年3月  
  • 松田 勇紀, 岸 太郎
    臨床精神薬理 18(10) 1269-1276 2015年10月  
    治療抵抗性うつ病に対する気分安定薬のlithium、バルプロ酸、carbamazepine、lamotrigine、topiramate、gabapentinの効果および安全性に関して、系統的レビューを行った。Lithium増強療法はプラセボをコントロールとした二重盲検無作為割付試験のみを包括したメタ解析で、lithium投与群はプラセボ投与群と比べて有意に治療反応者数が多く、その効果量はnumber needed to treat=5と大きかった。さらに、治療継続率もプラセボ投与群と比較して同等であった。Lithium増強療法は、治療抵抗性うつ病に対して、有効性・安全性ともに優れていると考察された。Lithium以外の気分安定薬は、無作為割付試験や非盲検試験の報告はあるが、メタ解析は行われておらず、エビデンスが乏しいと言わざるを得ない。そのため、治療抵抗性うつ病患者に対する気分安定薬の増強療法としては、lithiumが強く推奨される。(著者抄録)
  • 松田 勇紀, 大矢 一登, 松永 慎史, 岸 太郎, 岩田 仲生
    臨床精神薬理 18(6) 741-746 2015年6月  
    持続性注射剤は服薬アドヒアランス不良、再発を繰り返している統合失調症患者に対して、有効な治療法であることが示唆されている。Aripiprazole once-monthly(AOM)は持続性注射剤の中で初めてdopamine partial agonist作用を有する薬剤である。AOMは無作為割付試験の結果から、有効性評価項目ではプラセボ群と比べて、急性期では陽性症状、陰性症状、社会機能障害の改善を示した。維持期では再発予防および脱落までの期間を延長させた。またAOM群は経口aripiprazole群と比べて維持期における脱落率が低く、脱落までの期間を延長させる可能性が示唆された。安全性評価項目において急性期では、AOM群はプラセボ群と比べて体重増加を認めたが、維持期ではプラセボ群、経口aripiprazole群と変わらなかった。錐体外路症状は、急性期、維持期どちらにおいてもAOM群はプラセボ群、経口aripiprazole群と変わらなかった。これらより、AOMは有効性、安全性に優れた薬剤であることが示唆された。(著者抄録)
  • 松田 勇紀, 岸 太郎, 岩田 仲生
    Progress in Medicine 33(11) 2323-2328 2013年11月  

書籍等出版物

 3

講演・口頭発表等

 123

担当経験のある科目(授業)

 7

共同研究・競争的資金等の研究課題

 6

主要な社会貢献活動

 14

メディア報道

 4